Syed Zohad Shah: Reducing Blood Loss and Hospital Stays in Non-Cardiac Thoracic Surgery
Syed Zohad Shah, Peer Reviewer at Springer Nature, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in The Cardiothoracic Surgeon, adding:
“Excited to share our recently published systematic review and meta-analysis.
‘Optimizing hemostasis in thoracic surgery: a systematic review and meta-analysis of perioperative antifibrinolytic therapy.’
This study evaluated the efficacy and safety of perioperative antifibrinolytic therapy—including tranexamic acid (TXA) and aprotinin—in adult patients undergoing non-cardiac thoracic surgery.
Across 15 studies involving 2,169 patients, our analysis found that antifibrinolytic therapy was associated with:
- Reduced 24-hour postoperative blood loss
- Reduced total red blood cell transfusion volume
- Shorter hospital stay
- Consistent benefits in sensitivity analyses, including major thoracic procedures
- No significant increase in respiratory complications or reoperation for bleeding
The study also explored differences between intravenous and topical administration and between TXA and aprotinin, providing additional insight into perioperative blood conservation strategies.
I’m grateful to have contributed to this work through data extraction, data analysis, and interpretation of results, and to have worked alongside an excellent multidisciplinary team of researchers and clinicians.
Open Access Publication
Published in: The Cardiothoracic Surgeon (2026)
Research like this reinforces the importance of evidence-based approaches to improving perioperative outcomes and optimizing patient care.”
Title: Optimizing hemostasis in thoracic surgery: a systematic review and meta-analysis of perioperative antifibrinolytic therapy
Authors: Muhammad Hamza, Zohad Shah, Hasnain Wajeeh Saqib, Syeda Rabiah Shahid, Muhammad Murad Khurshid, Sheza Irfan, Aizaz Anwar Khalid, Arshdeep Singh, Ikram Ul Haq Chaudhry, Asif Raza Shah

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 29, 2026, 15:09Abdulbari Mohammed: The Basics of Antiphospholipid Syndrome
-
Aug 29, 2026, 15:06Laurent Arnaud: Rare SLE Manifestations Demand More Than Rare Attention – Insights from The Lancet Rheumatology
-
Aug 29, 2026, 14:55Marco Vitolo: The Changing Landscape of Sex Differences in AF-Related Stroke
-
Aug 29, 2026, 14:54Hiteshi K.C. Chauhan: Should Patients with AF and Intermediate Stroke Risk Receive Anticoagulation?
-
Aug 29, 2026, 14:39C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
-
Aug 29, 2026, 14:07Vincent Rizzo: Beta Blocker Choice May Impact Portal Vein Thrombosis and Survival in Cirrhosis
-
Aug 29, 2026, 14:04Günalp Uzun: DGTI 2026 New Insights in Platelet Immunology and Hemostasis
-
Aug 29, 2026, 13:59Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
-
Aug 29, 2026, 11:03Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines